Proof-of-concept preparation and characterization of dual-drug amorphous nanoparticle complex as fixed-dose combination of poorly soluble drugs

References

• Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med. 2008;31:213–224.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120:713–719.
   PubMed Web of Science ®Google Scholar
• Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med. 2008;23:611–614.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents a meta-analysis. Hypertension. 2010;55:399–407.
   PubMed Web of Science ®Google Scholar
• Hutchins V, Zhang B, Fleurence RL, et al. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin. 2011;27:1157–1168.
   PubMed Web of Science ®Google Scholar
• Laurent C, Kouanfack C, Koulla-Shiro S, et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet. 2004;364:29–34.
   PubMed Web of Science ®Google Scholar
• Monedero I, Caminero JA. Evidence for promoting fixed-dose combination drugs in tuberculosis treatment and control: a review. Int J Tuberc Lung Dis. 2011;15:433–439.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Dahl R, Buhl R, et al. Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients. Respir Med. 2014;108:1498–1507.
   PubMed Web of Science ®Google Scholar
• Kawabata Y, Wada K, Nakatani M, et al. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Int J Pharm. 2011;420:1.
   PubMed Web of Science ®Google Scholar
• Dengale SJ, Ranjan OP, Hussen SS, et al. Preparation and characterization of co-amorphous Ritonavir-Indomethacin systems by solvent evaporation technique: improved dissolution behavior and physical stability without evidence of intermolecular interactions. Eur J Pharm Sci. 2014;62:57–64.
   PubMed Web of Science ®Google Scholar
• Fule R, Dhamecha D, Maniruzzaman M, et al. Development of hot melt co-formulated antimalarial solid dispersion system in fixed dose form (ARLUMELT): evaluating amorphous state and in vivo performance. Int J Pharm. 2015;496:137–156.
   PubMedGoogle Scholar
• Suresh K, Mannava MKC, Nangia A. A novel curcumin-artemisinin coamorphous solid: physical properties and pharmacokinetic profile. RSC Adv. 2014;4:58357–58361.
   Web of Science ®Google Scholar
• Trasi NS, Taylor LS. Thermodynamics of highly supersaturated aqueous solutions of poorly water-soluble drugsimpact of a second drug on the solution phase behavior and implications for combination products. J Pharm Sci. 2015;104:2583–2593.
   PubMed Web of Science ®Google Scholar
• Trasi NS, Taylor LS. Dissolution performance of binary amorphous drug combinations-Impact of a second drug on the maximum achievable supersaturation. Int J Pharm. 2015;496:282–290.
   PubMedGoogle Scholar
• Laitinen R, Lobmann K, Strachan CJ, et al. Emerging trends in the stabilization of amorphous drugs. Int J Pharm. 2013;453:65–79.
   PubMed Web of Science ®Google Scholar
• Chavan RB, Thipparaboina R, Kumar D, et al. Co amorphous systems: a product development perspective. Int J Pharm. 2016;515:403–415.
   PubMed Web of Science ®Google Scholar
• Alonzo D, Zhang G, Zhou D, et al. Understanding the behavior of amorphous pharmaceutical systems during dissolution. Pharm Res. 2010;27:608–618.
   PubMed Web of Science ®Google Scholar
• Jog R, Burgess DJ. Pharmaceutical amorphous nanoparticles. J Pharm Sci. 2017;106:39–65.
   PubMed Web of Science ®Google Scholar
• Matteucci ME, Brettmann BK, Rogers TL, et al. Design of potent amorphous drug nanoparticles for rapid generation of highly supersaturated media. Mol Pharm. 2007;4:782–793.
   PubMed Web of Science ®Google Scholar
• Dhumal RS, Biradar SV, Yamamura S, et al. Preparation of amorphous cefuroxime axetil nanoparticles by sonoprecipitation for enhancement of bioavailability. Eur J Pharm Biopharm. 2008; 9//70:109–115.
   PubMed Web of Science ®Google Scholar
• Mou DS, Chen HB, Wan JL, et al. Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility. Int J Pharm. 2011;413:237–244.
   PubMed Web of Science ®Google Scholar
• Miller MA, DiNunzio J, Matteucci ME, et al. Flocculated amorphous itraconazole nanoparticles for enhanced in vitro supersaturation and in vivo bioavailability. Drug Dev Ind Pharm. 2012;38:557–570.
   PubMed Web of Science ®Google Scholar
• Lindfors L, Skantze P, Skantze U, et al. Amorphous drug nanosuspensions. 1. Inhibition of Ostwald ripening. Langmuir 2006;22:906–910.
   PubMed Web of Science ®Google Scholar
• Arora A, Shafiq N, Jain S, et al. Development of sustained release "NanoFDC (fixed dose combination)" for hypertension – an experimental study. Plos One. 2015;10:e0128208.
   PubMed Web of Science ®Google Scholar
• Aryal S, Hu CMJ, Zhang LF. Combinatorial drug conjugation enables nanoparticle dual-drug delivery. Small. 2010;6:1442–1448.
   PubMed Web of Science ®Google Scholar
• Huang WT, Larsson M, Lee YC, et al. Dual drug-loaded biofunctionalized amphiphilic chitosan nanoparticles: Enhanced synergy between cisplatin and demethoxycurcumin against multidrug-resistant stem-like lung cancer cells. Eur J Pharm Biopharm. 2016;109:165–173.
   PubMed Web of Science ®Google Scholar
• Cheow WS, Hadinoto K. Self-assembled amorphous drug-polyelectrolyte nanoparticle complex with enhanced dissolution rate and saturation solubility. J Colloid Interface Sci. 2012;367:518–526.
   PubMed Web of Science ®Google Scholar
• Cheow WS, Hadinoto K. Green preparation of antibiotic nanoparticle complex as potential anti-biofilm therapeutics via self-assembly amphiphile-polyelectrolyte complexation with dextran sulfate. Colloids Surf B Biointerfaces. 2012;92:55–63.
   PubMed Web of Science ®Google Scholar
• Cheow WS, Kiew TY, Yang Y, et al. Amorphization strategy affects the stability and supersaturation profile of amorphous drug nanoparticles. Mol Pharm. 2014;11:1611–1620.
   PubMed Web of Science ®Google Scholar
• Nguyen MH, Yu H, Dong BX, et al. A supersaturating delivery system of silibinin exhibiting high payload achieved by amorphous nano-complexation with chitosan. Eur J Pharm Sci. 2016;89:163–171.
   PubMed Web of Science ®Google Scholar
• Nguyen MH, Yu H, Kiew TY, et al. Cost-effective alternative to nano-encapsulation: amorphous curcumin-chitosan nanoparticle complex exhibiting high payload and supersaturation generation. Eur J Pharm Biopharm. 2015;96:1–10.
   PubMed Web of Science ®Google Scholar
• Yousefpour P, Atyabi F, Farahani EV, et al. Polyanionic carbohydrate doxorubicin-dextran nanocomplex as a delivery system for anticancer drugs: in vitro analysis and evaluations. Int J Nanomed. 2011;6:1487–1496.
   PubMed Web of Science ®Google Scholar
• Dong BX, Hadinoto K. Amorphous nanoparticle complex of perphenazine and dextran sulfate as a new solubility enhancement strategy of antipsychotic perphenazine. Drug Dev Ind Pharm. 2017;43:996–1002.
   PubMed Web of Science ®Google Scholar
• Vitale RG, Afeltra J, de HGS, et al. In vitro activity of amphotericin B and itraconazole in combination with flucytosine, sulfadiazine and quinolones against Exophiala spinifera. J Antimicrob Chemother. 2003;51:1297–1300.
   PubMed Web of Science ®Google Scholar
• Skov M, Main KM, Sillesen IB, et al. Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide. Eur Respir J. 2002;20:127–133.
   PubMed Web of Science ®Google Scholar
• Steinhart AH, Feagan BG, Wong CJ, et al. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology. 2002;123:33–40.
   PubMed Web of Science ®Google Scholar
• Thiry J, Broze G, Pestieau A, et al. Investigation of a suitable in vitro dissolution test for itraconazole-based solid dispersions. Eur J Pharm Sci. 2016;85:94–105.
   PubMed Web of Science ®Google Scholar
• Prentice AG, Glasmacher A. Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother. 2005;56:i17–i22.
   PubMed Web of Science ®Google Scholar
• Lei QL, Hadinoto K, Ni R. Complexation of polyelectrolytes with hydrophobic drug molecules in salt-free solution: theory and simulations. Langmuir. 2017;33:3900–3909.
   PubMed Web of Science ®Google Scholar
• PubChem Compound Database 2017 (https://pubchem.ncbi.nlm.nih.gov/compound) by National Center for Biotechnology Information (Accessed 8 November 2017) [Internet]. [cited 8 November 2017].
   Google Scholar
• Turel I, Bukovec P, Quiros M. Crystal structure of ciprofloxacin hexahydrate and its characterization. Int J Pharm. 1997;152:59–65.
   Web of Science ®Google Scholar
• Singh A, Bharati A, Frederiks P, et al. Effect of compression on the molecular arrangement of itraconazole-soluplus solid dispersions: induction of liquid crystals or exacerbation of phase separation? Mol Pharm. 2016;13:1879–1893.
   PubMed Web of Science ®Google Scholar